*Abbreviations used in this paper:* HA, hemagglutinin; NOD, nonobese diabetic; RIP, rat insulin promoter.

Introduction
============

Nonobese diabetic (NOD) mice are thought to represent a suitable animal model of human type 1 diabetes ([@bib1], [@bib2]). In this model, the disease depends on the activation of autoimmune T cells by peptides presented by the particular NOD class II (g7) MHC allele that controls disease. In addition, several T cell receptor transgenic models of type 1 diabetes have been developed in which particularly high frequencies of CD4 or CD8 T cells specific for antigens expressed in β cells cause pancreatic islet cell infiltration with subsequent destruction of β cells ([@bib3], [@bib4]). In the NOD and in some transgenic models ([@bib3], [@bib5], [@bib6]), the disease can be precipitated when CD4 T cells from diabetic mice are transferred into immunodeficient recipients where diabetes develops within 1--2 wk. Nevertheless, the mechanism of β cell destruction has remained obscure. It became clear that perforin-deficient NOD mice exhibited a delayed onset of disease ([@bib7], [@bib8]), but it was not obvious whether the late phase of β cell destruction was affected. On the other hand, it was shown that Fas-deficient lpr/lpr mice on the NOD background did not develop diabetes ([@bib9]). Additional analyses had suggested that Fas was present on β cells ([@bib9]) and that expression increased during development of the disease. Other studies, however, also revealed that in Fas-deficient NOD mice there was no infiltration of pancreatic islets by mononuclear cells ([@bib10]), thus leaving open the question of whether Fas was directly involved in β cell death. More recent studies using a dominant negative *Fas* mutation ([@bib11]) or in vivo anti-Fas L antibody treatment ([@bib12]) were interpreted to indicate that Fas may have a role in promoting predominantly early stages of the disease. To address a potential role of Fas in β cell destruction conclusively, we have produced a conditional *Fas* allele (fas^fl^) in which the death domain-encoding exon 9 is flanked by loxP sites, allowing for cell type--specific Fas inactivation (unpublished data). To analyze whether Fas inactivation in pancreatic β cells resulted in resistance to the development of diabetes, the fas^fl^ allele and a rat insulin promoter (RIP)--controlled Cre transgene ([@bib13]) were introduced into a transgenic model of type 1 diabetes in which a transgenic TCR recognizes peptide 111--119 of influenza hemagglutinin (HA) expressed under control of the RIP and presented by class II E^d^ MHC molecules (TCR-HA, Ins-HA) ([@bib5]). The onset and development of diabetes in I-E^d^ homozygous mice carrying the five transgenes (TCR-HA^+/−^, Ins-HA^+/−^, Fas^fl/fl^, RIP-Cre^+/−^ mice) was compared with that in mice with only four transgenes lacking the RIP-cre transgene (TCR-HA^+/−^, Ins-HA^+/−^, Fas^fl/fl^, RIP-Cre^−/−^ mice) and thereby expressing Fas in β cells.

Materials and Methods
=====================

Mice and Genotyping.
--------------------

TCR-HA mice and Ins-HA mice were bred as heterozygous transgenic mice and are on the BALB/c background. Fas^fl^ mice derived from C57Bl/6 were created by homologous recombination using a conditional *Fas* allele in which the exon 9 has been flanked by loxP sites. RIP-Cre mice were on a mixed 129sv, C57Bl/6, and DBA-2 background ([@bib13]). All animals were maintained in a pathogen-free facility in accordance with the guidelines of the Committee on Animals of Harvard Medical School. Genotyping of transgenes was determined by PCR on tail DNA. Primer sequences were 5′-GGCTACCATGCGAACAATTCACCCG-3′ and 5′-CTCCGTCAGCCATAGCAAATTTCTG-3′ for the *HA* transgene, 5′-ACAAGGTGGCAGTAACAGGA-3′ and 5′-ACAGTCAGTCTGGTTCCTGA-3′ for the *TCR-HA* transgene, 5′-CGATGCAACGAGTGATGAGG-3′ and 5′-CATCGCTCGACCAGTTTAGT-3′ for the *Cre* transgene, and 5′-TGCAGTTGCTGAGATGAACCATTTTCTCTGTCT-3′ (P1) and 5′-GGCTTTGGAAAGGAATTTCCTCCTAAGAGG-3′ (P2) for WT and floxed *Fas* alleles. A 430-bp amplified product indicated the presence of a WT *Fas* allele, whereas a 470-bp amplified product indicated the presence of a floxed *Fas* allele, since the sense primer was located in exon 9 and the antisense one 3′ to the loxP site downstream of exon 9 ([Fig. 1](#fig1){ref-type="fig"} A). Homozygosity for I-E^d^ was determined by staining peripheral blood leukocytes.

![Successful elimination of the floxed *Fas*--exon 9 by homologous recombination in pancreatic β cells. (A) Representation of WT *Fas*, floxed *Fas*, and recombined floxed *Fas* alleles, and location of the primers used in PCR analyses. Cre-mediated recombination of the floxed *Fas* allele results in the deletion of exon 9. (B) PCR analysis on DNA from liver, heart, thymus, and purified islets of one Fas^fl^ homozygous and one Fas^fl^ homozygous, RIP-Cre heterozygous mouse.](20030698f1){#fig1}

RIP-Cre--mediated Fas Recombination in Islet DNA.
-------------------------------------------------

DNA was prepared from the thymus, liver, heart, and islets isolated at the Harvard Medical School Islet Core Rodent Isolation. RIP-Cre--mediated *Fas* recombination was assessed using a sense primer with the sequence 5′-GTCCTCTATTATCCTCATCATGAG-3′ (P3) located upstream of the 5′ loxP site and the antisense primer located downstream of the 3′ loxP site (P2). A 1.7-kb amplified product indicated the presence of intact exon 9, whereas a 260-bp amplified product indicated the presence of a deleted exon 9.

Diabetes Monitoring and Cyclophosphamide Administration.
--------------------------------------------------------

Development of spontaneous diabetes was assessed by measuring blood glucose twice a week with an automatic glucometer (Accu-chek Advantage; Roche). Cyclophosphamide (Sigma-Aldrich) in PBS was injected intraperitoneally at a dose of 200 mg/kg. Blood glucose levels of cyclophosphamide-treated mice were monitored daily.

Adoptive Transfer of Diabetes.
------------------------------

CD4^+^ TCR-HA--expressing cells were purified by sorting lymphocytes from spleen and LN of RAG-2^−/−^, TCR-HA^+/−^ mice stained with the 6.5 (anti--TCR-HA) and anti-CD4 (GK1.5; BD Biosciences) mAbs. 10^5^ sorted 6.5^+^CD4^+^ cells were i.v. injected into either RAG-2^−/−^, Fas^fl/fl^, Rip-cre^+/−^, Ins-HA^+/−^ or RAG-2^−/−^, Fas^fl/fl^, Rip-cre^−/−^, Ins-HA^+/−^ mice. Blood glucose levels of the recipients were tested daily.

Results and Discussion
======================

The efficacy and tissue specificity of Cre-mediated deletion of *Fas*--exon 9 was assessed by PCR on DNA prepared from purified islets and various tissues from Cre-expressing and -nonexpressing Fas^fl^ homozygous mice. [Fig. 1](#fig1){ref-type="fig"} A depicts a schematic representation of mutated and WT *Fas* alleles and the position of the primers used to assess littermate genotype and β cell-specific loss of functional *Fas* allele. [Fig. 1](#fig1){ref-type="fig"} B shows that, regardless of Cre expression, DNA of nonpancreatic origin yielded a single 1.7-kb P2/P3 PCR product indicative of the sole presence of *Fas*--exon 9 ([Fig. 1](#fig1){ref-type="fig"} A). Even traces of recombined *Fas*--exon 9 would have been detected by the presence of a 260-bp fragment, which because of its short size would be favored over the 1.7-kb fragment. Evidence for islet-specific Cre-mediated deletion of exon 9 came from the single 260-bp P2/P3 PCR product that was obtained from islets of Cre-expressing mice, whereas a single 1.7-kb band was detected from the islets of Cre-nonexpressing mice. PCR analysis of the same samples using the P1/P2 primers that hybridize to WT nonrecombined but not to recombined *Fas* alleles ([Fig. 1](#fig1){ref-type="fig"} A) yielded a single 470-bp band in nonpancreatic tissues of mice irrespective of RIP-Cre expression and in islets of mice lacking RIP-Cre ([Fig. 1](#fig1){ref-type="fig"} B). A much fainter 470-bp band was seen in islets of Cre-expressing mice ([Fig. 1](#fig1){ref-type="fig"} B). This faint band is likely to reflect the fact that whole islets such as those used in the present study contain cells other than β cells (∼30%), e.g., non--β endocrine cells, macrophages, endothelial cells, etc., lacking Cre expression. Thus, the absence of amplification of a 260-bp P2/P3 PCR product (which will be favored over the 1.7-kb P2/P3 PCR product) in nonpancreatic tissues and its detection only in Cre-expressing islets and the diminution of the 470-bp fragment intensity in Cre-expressing islets strongly suggest that the RIP-Cre--mediated recombination resulted in tissue-specific deletion of functional Fas in the vast majority of β cells. Since the development of diabetes with blood sugar levels exceeding 200 mg/dl requires destruction of well over 50% of all β cells, the conditional knockout was suitable to reveal a possible essential role of Fas in the development of diabetes, since any Fas-dependent destruction of β cells could not exceed 50% in these particular mice, and thus be insufficient to result in diabetes. Previous work using a RIP-Cre transgenic mouse line identical to that of the present study could not find evidence for a toxic effect of the transgene to the β cells, their function, or the glucose tolerance of RIP-Cre transgenic mice ([@bib13], [@bib14]). Furthermore, the Fas^fl^ heterozygous, TCR-HA, Ins-HA, RIP-Cre transgenic breeders used in this study to generate the Fas-competent and -deficient TCR-HA, Ins-HA mice behaved identically to TCR-HA, Ins-HA double transgenic mice with respect to diabetes development, fertility, and frequency of the expected genotypes among their litter. Thus, we could exclude a role for the RIP-Cre transgene in potential phenotypical differences between RIP-Cre--expressing and --nonexpressing mice. To assess the impact of Fas expression by β cells in their T cell--mediated destruction, we compared the development of spontaneous autoimmune diabetes in the TCR-HA, Ins-HA transgenic model in which the floxed *Fas* alleles are recombined by the Cre recombinase (TCR-HA^+/−^, Ins-HA^+/−^, Fas^fl/fl^, RIP-Cre^+/−^ mice) to that of transgenic littermates lacking Cre expression (TCR-HA^+/−^, Ins-HA^+/−^, Fas^fl/fl^, RIP-Cre^−/−^ mice) ([Fig. 2](#fig2){ref-type="fig"}) . The incidence and onset of diabetes in the latter quadruple transgenic littermates was not different from that in TCR-HA, Ins-HA double transgenic mice, indicating that neither the introduced floxed *Fas* alleles nor the mixed genetic background brought by the Fas floxed and RIP-Cre transgenic mice did perturb autoimmunity. The elimination of *Fas* by Cre recombinase did not produce a delay in the onset but some acceleration of the onset of diabetes ([Fig. 2](#fig2){ref-type="fig"}). A similar conclusion, namely that Fas deficiency did not delay the onset of diabetes, was reached when diabetes was analyzed in TCR-HA, Ins-HA mice transgenic mice with a β cell--specific deletion of *Fas* that were treated with 200 mg/kg cyclosphosphamide. This treatment is known to precipitate diabetes in NOD and TCR-HA, Ins-HA mice with similar kinetics, perhaps by interfering with regulatory (suppressive) T cells that control the development of disease. The RIP-Cre--expressing mice came down with diabetes 4--5 d after treatment with the drug, indicating that also under these conditions Fas did not play a discernible role in β cell death caused by autoimmune T cells ([Fig. 3](#fig3){ref-type="fig"}) . Finally, it was tested whether purified CD4^+^ TCR-HA--expressing T cells from TCR-HA transgenic RAG-2^−/−^ mice could cause β cell destruction in the absence of CD8^+^ T cells by transferring them into Ins-HA transgenic mice on the RAG-2^−/−^ background lacking or expressing fas on β cells. As shown in [Fig. 4](#fig4){ref-type="fig"} , diabetes developed in both types of recipients within a short time period after injection of 10^5^ CD4^+^ T cells.

![Effective destruction of β-islet cells from Fas-deficient and Fas-competent TCR-HA, Ins-HA transgenic mice. Blood glucose levels of Fas^fl/fl^, Rip-Cre^+/−^, TCR-HA^+/−^, Ins-HA^+/−^ (▪, *n* = 46) and Fas^fl/fl^, Rip-Cre^−/−^, TCR-HA^+/−^, Ins-HA^+/−^ (⋄, *n* = 63) mice were assessed over a period of 32 wk. Mice were considered diabetic after two successive blood glucose measurements ≥300 mg/dl.](20030698f2){#fig2}

![Cyclophosphamide-induced diabetes in TCR-HA^+/−^, Ins-HA^+/−^, Fas^fl/fl^, RIP-Cre^+/−^ mice. Mice (*n* = 10) were injected with 200 mg/kg of cyclophosphamide on day 0 and monitored for their blood glucose levels every day.](20030698f3){#fig3}

![Development of diabetes in Fas-deficient and Fas-competent RAG-2^−/−^, Ins-HA^+/−^ recipients injected with CD4^+^ TCR-HA transgenic cells. 6.5^+^CD4^+^ cells from RAG-2^−/−^, TCR-HA^+/−^ mice were sorted, and 10^5^ cells were transferred into RAG-2^−/−^, Fas^fl/fl^, Rip-cre^+/−^, Ins-HA^+/−^ (•, *n* = 4) and RAG-2^−/−^, Fas^fl/fl^, Rip-cre^−/−^, Ins-HA^+/−^ (▵, *n* = 4) on day zero. Blood glucose levels were monitored daily.](20030698f4){#fig4}

In both the NOD model ([@bib2]) and in several TCR transgenic models ([@bib3], [@bib5], [@bib6]), the autoimmune disease can be transferred with purified CD4 T cells into immunodeficient mice that themselves do not have any T cells. Since only a few activated CD4^+^ T cells express perforin but most express Fas ligand, it was conceivable that such T cells destroyed β cells by a Fas L--Fas interaction that required direct cell contact. Our findings refute this hypothesis and are consistent with the notion that β cells from Fas-deficient mice that were transplanted into Fas-competent mice are effectively destroyed by diabetogenic T cells ([@bib14]--[@bib16]) even though it is not clear in the latter scenario whether destruction of the transplanted β cells occurs by the same mechanism as that of β cells in situ. Our results are also consistent with the finding that a dominant negative *Fas* transgene in NOD mice had little effect on the development of diabetes when splenocytes from diabetic animals were transferred into x-irradiated transgenic nondiabetic recipients ([@bib11]).

By eliminating the Fas L--Fas apoptotic system as the essential mediator of β cell death in type 1 diabetes, our results should shift the focus to other mediators of apoptotic cell death that do not require direct contact between T cells and β cells. With regard to this notion, we may point out that there is apparently no significant expression of class II MHC on β islet cells ([@bib1]) and perhaps even more conclusively that antigen-specific contact between T cells and β cells is not required for the T cell--mediated destruction of β cells ([@bib17]). Thus, the search for mediators of β cell destruction needs to focus on molecules that play an essential role in β cell destruction in type 1 autoimmune diabetes and differ from Fas. The identification of such essential mediators of β cell death would perhaps permit interference with the disease once the process of destruction has begun and first symptoms are detectable.
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